Brief: Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing
28/03/2025 20:11
March 28 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX PHARMACEUTICALS INC - EXPECTS $400 MILLION IMPAIRMENT CHARGE FOR VX-264 - SEC FILING Source text: [ID:n0000875320-25-000156] Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31